Bivalirudin, glycoprotein inhibitor, and heparin use and association with outcomes of primary percutaneous coronary intervention in the United Kingdom.

AIMS The HORIZONS trial reported a survival advantage for bivalirudin over heparin-with-glycoprotein inhibitors (GPIs) in primary PCI for ST elevation myocardial infarction. This drove an international shift in clinical practice. Subsequent studies have produced divergent findings on mortality benefits with bivalirudin. We investigated this issue in a larger population than studied in any of these trials, using the United Kingdom national PCI registry. METHODS AND RESULTS 61 136 primary PCI procedures were performed between January 2008 and January 2012. Demographic and procedural data were obtained from the registry. Mortality information was obtained through the UK Office of National Statistics. Multivariable logistic regression and propensity analysis modelling were utilized to study the association of different anti-thrombotic strategies with outcomes. Unadjusted data demonstrated near-identical survival curves for bivalirudin and heparin-plus-GPI groups. Significantly higher early and late mortality was found in patients treated with heparin alone ( ITALIC! P < 0.0001) but this group had a markedly higher baseline risk. After propensity matching, the bivalirudin vs. heparin-plus-GPI groups still demonstrated very similar adjusted mortality (odds ratio 1.00 at 30 days, and 0.96 at 1 year). Patients treated with heparin alone continued to show higher mortality after adjustment, although effect size was considerably diminished (odds ratio vs. other groups 1.17-1.24 at 30 days). CONCLUSIONS Analysis of recent UK data showed no significant difference in short- or medium-term mortality between ST elevation myocardial infarction patients treated with bivalirudin vs. heparin-plus-GPI at primary PCI.

[1]  P. Jüni,et al.  Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[2]  M. Valgimigli,et al.  Bivalirudin versus heparin in patients with acute myocardial infarction: A meta‐analysis of randomized trials , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  G. Stone,et al.  Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. , 2015, JAMA.

[4]  B. Gersh,et al.  Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. , 2015, Journal of the American College of Cardiology.

[5]  Mike Fisher,et al.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial , 2014, The Lancet.

[6]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  S. Pocock,et al.  Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). , 2014, Journal of the American College of Cardiology.

[8]  S. Pocock,et al.  Bivalirudin started during emergency transport for primary PCI. , 2013, The New England journal of medicine.

[9]  G. Stone,et al.  Leukocyte Count Is a Modulating Factor for the Mortality Benefit of Bivalirudin in ST-Segment–Elevation Acute Myocardial Infarction: The HORIZONS-AMI Trial , 2013, Circulation. Cardiovascular interventions.

[10]  A. Castro‐Beiras,et al.  Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding risk scores in STEMI undergoing primary PCI: insights from a cohort of 1391 patients , 2013, European heart journal. Acute cardiovascular care.

[11]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[12]  G. Stone,et al.  Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. , 2012, Journal of the American College of Cardiology.

[13]  S. Normand,et al.  Bivalirudin Therapy Is Associated With Improved Clinical and Economic Outcomes in ST-Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: Results From an Observational Database , 2012, Circulation. Cardiovascular quality and outcomes.

[14]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[15]  Jörg Hausleiter,et al.  Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. , 2011, The New England journal of medicine.

[16]  P. Ludman British Cardiovascular Intervention Society Registry for audit and quality assessment of percutaneous coronary interventions in the United Kingdom , 2011, Heart.

[17]  J. Hagenaars,et al.  The Multiple Propensity Score as Control for Bias in the Comparison of More Than Two Treatment Arms: An Introduction From a Case Study in Mental Health , 2010, Medical care.

[18]  G. De Luca,et al.  Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. , 2009, Journal of the American College of Cardiology.

[19]  S. Nekolla,et al.  Abciximab in Patients With Acute ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial , 2009, Circulation.

[20]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[21]  E. Antman,et al.  Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. , 2005, JAMA.

[22]  V. Hasselblad,et al.  Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. , 2004, American heart journal.